NCT00895570View on ClinicalTrials.gov

The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Sleep RestrictionImpaired Glucose Metabolism
Interventions
DRUG

modafinil

During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).

DRUG

placebo

During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT00895570 - The Effects of Modafinil to Counteract the Adverse Metabolic Consequences of Sleep Restriction | Biotech Hunter | Biotech Hunter